Aidé Tamara Staines-Boone

Aidé Tamara Staines-Boone

Auto-generated profile, based on publicly available information

Aidé Tamara Staines-Boone

Departamento de Inmunología Pediátrica, Instituto Mexicano del Seguro Social Unidad Médica de Alta Especialidad N°25, Monterrey, México

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
ELEduardo Liquidano‐Perez
Eduardo Liquidano‐Perez
GMGibert Maza‐Ramos
Gibert Maza‐Ramos
BABethy Alexandra Perez Arias
Bethy Alexandra Perez Arias
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes
TBTania Barragán-Arévalo
Tania Barragán-Arévalo
MGMaria Edith Gonzalez‐Serrano
Maria Edith Gonzalez‐Serrano

29 July 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
ASAidé Tamara Staines-Boone
Aidé Tamara Staines-Boone
MTMiyuki Tsumura
Miyuki Tsumura
ARAdriana de J Rodríguez
Adriana de J Rodríguez
DCDiana Olguín Calderón
Diana Olguín Calderón
LRLaura Berrón Ruiz
Laura Berrón Ruiz
LGLizbeth Blancas Galicia
Lizbeth Blancas Galicia
A heterozygous STAT1 mutation (K410E) was identified in a child with disseminated coccidioidomycosis. This report highlights the critical role of IFN-γ–mediated immunity in controlling fungal infections and expands the known phenotypic spectrum of autosomal dominant STAT1 deficiency.

5 May 2021 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes
NPNina Pastor
Nina Pastor
EGEdith González-Serrano
Edith González-Serrano
MYMarco Yamazaki-Nakashimada
Marco Yamazaki-Nakashimada
SSSelma Scheffler-Mendoza
Selma Scheffler-Mendoza
MEMario Ernesto Ernesto
Mario Ernesto Ernesto
Mutations in recombinase activating genes 1 and 2 (RAG1/2) result in human severe combined immunodeficiency (SCID). The products of these genes are essential for V(D)J rearrangement of the antigen receptors during lymphocyte development. Mutations resulting in null-recombination activity in RAG1 or RAG2 are associated with the most severe clinical and immunological phenotypes, whereas patients with hypomorphic mutations may develop leaky SCID, including Omenn syndrome (OS). A group of previously unrecognized clinical phenotypes associated with granulomata and/or autoimmunity have been described as a consequence of hypomorphic mutations. Here, we present six patients from unrelated families with missense variants in RAG1 or RAG2. Phenotypes observed in these patients ranged from OS to severe mycobacterial infections and granulomatous disease. Moreover, we report the first evidence of two variants that had not been associated with immunodeficiency. This study represents the first case series of RAG1- or RAG2-deficient patients from Mexico and Latin America.

24 January 2022 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ASAidé Tamara Staines‐Boone
Aidé Tamara Staines‐Boone
MGMaría Guadalupe González‐Villareal
María Guadalupe González‐Villareal
MPMaría Teresa Pompa‐Garza
María Teresa Pompa‐Garza
TMTeodoro Muñiz‐Ronquillo
Teodoro Muñiz‐Ronquillo
ASAdriana Carolina Sandoval‐González
Adriana Carolina Sandoval‐González
SRSaúl Oswaldo Lugo Reyes
Saúl Oswaldo Lugo Reyes

6 October 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
TOTiago Santos de Oliveira
Tiago Santos de Oliveira
RSRanieri Coelho Salgado
Ranieri Coelho Salgado
LGLillian Nunes Gomes
Lillian Nunes Gomes
CSCarolina Sánchez-Rodríguez
Carolina Sánchez-Rodríguez
JFJanáira Fernandes Severo Ferreira
Janáira Fernandes Severo Ferreira
ACAntonio Condino-Neto
Antonio Condino-Neto
Chronic granulomatous disease (CGD) is an inborn error of immunity (IEI) caused by mutations in genes encoding components of the NADPH oxidase complex, leading to defective microbial killing and increased susceptibility to infections. This study analyzed clinical, genetic, and geospatial data from 238 CGD patients across eight Latin American countries. Genetic variants were identified in 141 patients (59%), with XL-CGD being the most common form (77%). Pneumonia (80%), lymphadenopathy (63%), and skin infections (55.5%) were frequent, with bacteria and fungi, such as Staphylococcus aureus, Aspergillus spp., and mycobacteria, as major pathogens. Antimicrobial prophylaxis was widely used, while IFN-γ was mainly prescribed in Mexico, mainly in cases of classic CGD (XL-CGD). Hematopoietic stem cell transplantation (HSCT) did not improve survival compared to prophylaxis. The leading cause of death was infection, particularly pneumonia and sepsis. XL-CGD patients had worse survival outcomes. The study highlights the need for improved genetic diagnosis, newborn screening, regional treatment guidelines, and expanded access to HSCT.

18 July 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
TCTiareth Cova-Guzmán
Tiareth Cova-Guzmán
DRDeborah Palacios Reyes
Deborah Palacios Reyes
CRCarla M. Roman-Montes
Carla M. Roman-Montes
MYMarco Yamazaki-Nakashimada
Marco Yamazaki-Nakashimada
ABAidé Tamara Staines Boone
Aidé Tamara Staines Boone
LGLizbeth Blancas Galicia
Lizbeth Blancas Galicia
In chronic granulomatous disease (CGD), Aspergillus is the most common cause of invasive fungal infections and accounts for a high percentage of mortality. We recruited 45 patients of CGD with invasive aspergillosis (IA) events. The median age between the first CGD manifestation and first aspergillosis event was 65 mo. Mortality rate was 57.7% for proven aspergillosis events, 23.1% for probable events, and 19.2% for possible events (p = 0.038). Aspergillus fumigatus was the most common species. Comparing mortality with this cutoff point, 36% of those receiving 75 days (p = 0.05). 26 (58%) of the 45 patients died, out of which 18 (69%) had IA. Overall survival of the 45 patients was 80.8% at 64 mo. The high mortality rate of IA in CGD patients could be reduced by early suspicion, initiating correct antifungal treatment over a long period, and considering the performance of hematopoietic stem cell transplantation.